| 1 |
Sernicola A, Colpo A, Leahu AI, Alaibac M. Granulocyte Apheresis: Can It Be Associated with Anti PD-1 Therapy for Melanoma? Medicina 2022;58:1398. [DOI: 10.3390/medicina58101398] [Reference Citation Analysis]
|
| 2 |
Martínez AVC, Chiva LM, Villarino MR. Granulocyte and monocyte/macrophage apheresis for the treatment of immune-mediated inflammatory arthropathies: case reports. Drugs Context 2021;10:2021-8-5. [PMID: 34804171 DOI: 10.7573/dic.2021-8-5] [Reference Citation Analysis]
|
| 3 |
Woźniak M, Kurnatowska I, Małecka-Panas E, Talar-Wojnarowska R. Leukocytapheresis in patients with inflammatory bowel diseases. Prz Gastroenterol 2021;6:99-105. [PMID: 34276835 DOI: 10.5114/pg.2021.106658] [Reference Citation Analysis]
|
| 4 |
Domènech E, Grífols JR, Akbar A, Dignass AU. Use of granulocyte/monocytapheresis in ulcerative colitis: A practical review from a European perspective. World J Gastroenterol 2021; 27(10): 908-918 [PMID: 33776362 DOI: 10.3748/wjg.v27.i10.908] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 5 |
Saniabadi AR, Tanaka T, Yamamoto T, Kruis W, Sacco R. Granulomonocytapheresis as a cell-dependent treatment option for patients with inflammatory bowel disease: Concepts and clinical features for better therapeutic outcomes. J Clin Apher. 2019;34:51-60. [PMID: 30407662 DOI: 10.1002/jca.21670] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 6 |
Jean L, Audrey M, Beauchemin C, Consortium OBOTI. Economic Evaluations of Treatments for Inflammatory Bowel Diseases: A Literature Review. Can J Gastroenterol Hepatol 2018;2018:7439730. [PMID: 30009158 DOI: 10.1155/2018/7439730] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 7 |
Iida T, Ikeya K, Kato M, Abe J, Yamamoto M, Watanabe F, Sugimoto K, Hanai H. Adsorptive Depletion of Myeloid Lineage Leucocytes as Remission Induction Therapy in Patients with Ulcerative Colitis after Failure of First-Line Medications: Results from a Three-Year Real World, Clinical Practice. Digestion 2017;96:119-26. [PMID: 28796990 DOI: 10.1159/000479502] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 8 |
Imperiali G, Amato A, Terpin MM, Beverina I, Bortoli A, Devani M, Viganò C; Study Group on IBD (GSMII) . Granulocyte-Monocyte Apheresis in Steroid-Dependent, Azathioprine-Intolerant/Resistant Moderate Ulcerative Colitis: A Prospective Multicenter Study. Gastroenterol Res Pract 2017;2017:9728324. [PMID: 29403531 DOI: 10.1155/2017/9728324] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 9 |
Pillai N, Dusheiko M, Burnand B, Pittet V. A systematic review of cost-effectiveness studies comparing conventional, biological and surgical interventions for inflammatory bowel disease. PLoS One. 2017;12:e0185500. [PMID: 28973005 DOI: 10.1371/journal.pone.0185500] [Cited by in Crossref: 67] [Cited by in F6Publishing: 67] [Article Influence: 11.2] [Reference Citation Analysis]
|
| 10 |
Tanaka T, Yamamoto T, Sawada K, Sacco R. Treatment options for children and adolescents with inflammatory bowel disease: is granulomonocytapheresis an effective alternative to drug therapy? Expert Rev Gastroenterol Hepatol 2017;11:749-58. [PMID: 28612637 DOI: 10.1080/17474124.2017.1341309] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 11 |
Cabriada J, Rodríguez-lago I. Granulocitoaféresis en 2017. Puesta al día. Enfermedad Inflamatoria Intestinal al Día 2017;16:62-69. [DOI: 10.1016/j.eii.2016.12.001] [Reference Citation Analysis]
|
| 12 |
Aldeguer X, Sicras-mainar A. Costs of ulcerative colitis from a societal perspective in a regional health care area in Spain: A database study. Gastroenterología y Hepatología (English Edition) 2016;39:9-19. [DOI: 10.1016/j.gastre.2016.01.002] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 13 |
Aldeguer X, Sicras-Mainar A. Costs of ulcerative colitis from a societal perspective in a regional health care area in Spain: A database study. Gastroenterol Hepatol 2016;39:9-19. [PMID: 26211705 DOI: 10.1016/j.gastrohep.2015.04.007] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 14 |
Ghosh N, Premchand P. A UK cost of care model for inflammatory bowel disease. Frontline Gastroenterol 2015;6:169-74. [PMID: 28839807 DOI: 10.1136/flgastro-2014-100514] [Cited by in Crossref: 47] [Cited by in F6Publishing: 47] [Article Influence: 5.9] [Reference Citation Analysis]
|
| 15 |
Osada T, Watanabe S. Current Treatment Options for Inflammatory Bowel Diseases and Future Perspectives. Juntendo Medical Journal 2015;61:588-596. [DOI: 10.14789/jmj.61.588] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 16 |
De Cassan C, Savarino E, Marson P, Tison T, Hatem G, Sturniolo GC, D’Incà R. Granulo-monocyto apheresis is more effective in mild ulcerative colitis than in moderate to severe disease. World J Gastroenterol 2014; 20(45): 17155-17162 [PMID: 25493030 DOI: 10.3748/wjg.v20.i45.17155] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 17 |
Saniabadi AR, Tanaka T, Ohmori T, Sawada K, Yamamoto T, Hanai H. Treating inflammatory bowel disease by adsorptive leucocytapheresis: A desire to treat without drugs. World J Gastroenterol 2014; 20(29): 9699-9715 [PMID: 25110409 DOI: 10.3748/wjg.v20.i29.9699] [Cited by in CrossRef: 54] [Cited by in F6Publishing: 57] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 18 |
Ravasio R, De Silvestro G, Saggioro A, Sturniolo GC, Vernia P. Valutazione economica del sistema di aferesi per la rimozione di granulociti e macrofagi (Adacolumn®) rispetto a biologico nel trattamento della colite ulcerosa moderata-severa in pazienti steroido-dipendenti o resistenti in Italia. G Ital Health Technol Assess 2013;6:55-64. [DOI: 10.1007/s40269-013-0008-y] [Reference Citation Analysis]
|
| 19 |
Tanaka T, Sugiyama S, Goishi H, Kajihara T, Akagi M, Miura T. Treatment of children and adolescents with ulcerative colitis by adsorptive depletion of myeloid lineage leucocytes as monotherapy or in combination with low dose prednisolone after failure of first-line medications. BMC Gastroenterol. 2013;13:130. [PMID: 23961883 DOI: 10.1186/1471-230x-13-130] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 20 |
Tanaka T, Sugiyama S, Goishi H, Kajihara T, Akagi M, Miura T. Treatment of children and adolescents with ulcerative colitis by adsorptive depletion of myeloid lineage leucocytes as monotherapy or in combination with low dose prednisolone after failure of first-line medications. BMC Gastroenterol. 2013;13:130. [PMID: 23961883 DOI: 10.1016/s1873-9946(13)60351-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 21 |
Tominaga K, Nakano M, Hoshino M, Kanke K, Hiraishi H. Efficacy, safety and cost analyses in ulcerative colitis patients undergoing granulocyte and monocyte adsorption or receiving prednisolone. BMC Gastroenterol. 2013;13:41. [PMID: 23452668 DOI: 10.1186/1471-230x-13-41] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 22 |
Vecchi M, Vernia P, Riegler G, D’Incà R, Annese V, Bagnoli S. Therapeutic landscape for ulcerative colitis: where is the Adacolumn(®) system and where should it be? Clin Exp Gastroenterol. 2013;6:1-7. [PMID: 23323022 DOI: 10.2147/ceg.s33275] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 23 |
Cabriada JL. Aféresis en enfermedad inflamatoria intestinal. ¿Una opción válida? Gastroenterología y Hepatología 2012;35:22-31. [DOI: 10.1016/j.gastrohep.2011.10.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 24 |
Hanai H, Takeda Y, Eberhardson M, Gruber R, Saniabadi AR, Winqvist O, Lofberg R. The mode of actions of the Adacolumn therapeutic leucocytapheresis in patients with inflammatory bowel disease: a concise review. Clin Exp Immunol. 2011;163:50-58. [PMID: 21078086 DOI: 10.1111/j.1365-2249.2010.04279.x] [Cited by in Crossref: 65] [Cited by in F6Publishing: 72] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 25 |
Hanai H, Takeda Y, Eberhardson M, Gruber R, Saniabadi AR, Winqvist O, Lofberg R. The mode of actions of the Adacolumn therapeutic leucocytapheresis in patients with inflammatory bowel disease: a concise review. Clin Exp Immunol 2011;163:50-8. [PMID: 21078086 DOI: 10.1111/j.1365-2249.2010.04279.x] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 26 |
Ibargoyen-Roteta N, Gutiérrez-Ibarluzea I, Rico-Iturrioz R, López-Argumedo M, Reviriego-Rodrigo E, Cabriada-Nuño JL, Schünemann HJ. The GRADE approach for assessing new technologies as applied to apheresis devices in ulcerative colitis. Implement Sci 2010;5:48. [PMID: 20553616 DOI: 10.1186/1748-5908-5-48] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 27 |
Dignass AU, Eriksson A, Kilander A, Pukitis A, Rhodes JM, Vavricka S. Clinical trial: five or ten cycles of granulocyte-monocyte apheresis show equivalent efficacy and safety in ulcerative colitis. Aliment Pharmacol Ther 2010;31:1286-95. [PMID: 20331579 DOI: 10.1111/j.1365-2036.2010.04295.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 28 |
Cabriada JL, Ibargoyen N, Hernández A, Bernal A, Castiella A. Sustained remission after steroids and leukocytapheresis induced response in steroid-dependent ulcerative colitis: results at 1 year. Dig Liver Dis 2010;42:432-5. [PMID: 19833566 DOI: 10.1016/j.dld.2009.09.001] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 29 |
Cohen RD, Yu AP, Wu EQ, Xie J, Mulani PM, Chao J. Systematic review: the costs of ulcerative colitis in Western countries. Aliment Pharmacol Ther 2010;31:693-707. [PMID: 20064142 DOI: 10.1111/j.1365-2036.2010.04234.x] [Cited by in Crossref: 176] [Cited by in F6Publishing: 146] [Article Influence: 13.5] [Reference Citation Analysis]
|
| 30 |
Nos P, Domènech E. Tratamiento con aféresis en la enfermedad inflamatoria intestinal. Gastroenterología y Hepatología 2009;32:509-18. [DOI: 10.1016/j.gastrohep.2009.01.183] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 31 |
Hibi T, Sameshima Y, Sekiguchi Y, Hisatome Y, Maruyama F, Moriwaki K, Shima C, Saniabadi AR, Matsumoto T. Treating ulcerative colitis by Adacolumn therapeutic leucocytapheresis: clinical efficacy and safety based on surveillance of 656 patients in 53 centres in Japan. Dig Liver Dis 2009;41:570-7. [PMID: 19211314 DOI: 10.1016/j.dld.2008.11.020] [Cited by in Crossref: 50] [Cited by in F6Publishing: 51] [Article Influence: 3.6] [Reference Citation Analysis]
|
| 32 |
Bresci G, Parisi G, Mazzoni A, Scatena F, Capria A. Granulocytapheresis versus methylprednisolone in patients with acute ulcerative colitis: 12-month follow up. J Gastroenterol Hepatol 2008;23:1678-82. [PMID: 18823440 DOI: 10.1111/j.1440-1746.2008.05595.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 33 |
Bresci G. Granulocytapheresis in the treatment of patients with active ulcerative colitis. Expert Rev Gastroenterol Hepatol 2008;2:639-43. [PMID: 19072341 DOI: 10.1586/17474124.2.5.639] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 34 |
Tanaka T, Okanobu H, Yoshimi S, Murakami E, Kogame A, Imagawa H, Numata Y, Kuga Y, Moriya T, Ohya T, Kajiyama G. In patients with ulcerative colitis, adsorptive depletion of granulocytes and monocytes impacts mucosal level of neutrophils and clinically is most effective in steroid naïve patients. Dig Liver Dis 2008;40:731-6. [PMID: 18387860 DOI: 10.1016/j.dld.2008.02.012] [Cited by in Crossref: 49] [Cited by in F6Publishing: 52] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 35 |
Hanai H, Iida T, Takeuchi K, Watanabe F, Maruyama Y, Kageoka M, Ikeya K, Yamada M, Kikuyama M, Iwaoka Y, Hirayama K, Nagata S, Sato Y, Hosoda Y. Intensive granulocyte and monocyte adsorption versus intravenous prednisolone in patients with severe ulcerative colitis: an unblinded randomised multi-centre controlled study. Dig Liver Dis 2008;40:433-40. [PMID: 18296130 DOI: 10.1016/j.dld.2008.01.007] [Cited by in Crossref: 32] [Cited by in F6Publishing: 35] [Article Influence: 2.1] [Reference Citation Analysis]
|
